Quick Summary (TL;DR)
Barricaid® is a specialized implant designed to reduce the risk of a recurrent herniated disc after lumbar microdiscectomy in carefully selected patients with large annular defects.
Here’s what matters most:
- A microdiscectomy removes disc material pressing on a nerve, but the tear in the disc wall may remain.
- Barricaid® acts as an annular closure device, reinforcing the defect to reduce re-herniation risk.
- Clinical studies show Barricaid® can significantly reduce symptomatic re-herniation and repeat surgery in the right patients (Thomé et al., 2018; Thomé et al., 2021).
- At Vertrae®, a comprehensive spine center specializing in minimally invasive and robotic spine surgery, Barricaid® is used selectively when anatomy and evidence strongly support it.
- Procedures are performed at Vertrae® Surgery Center, our spine-only outpatient facility designed for minimally invasive and motion-preserving procedures, allowing for coordinated recovery and same-day discharge when appropriate.
When a Herniated Disc Comes Back, Confidence Can Disappear.
Barricaid Helps Protect It.
You’ve already been through the pain, the sharp leg symptoms, the MRI, the surgery, and the rehab.
You got your life back. But then, one movement, one twist, and suddenly, it’s happening again.
Another herniated disc. Another interruption.
At Vertrae®, a comprehensive spine center specializing in minimally invasive and robotic spine surgery, we’ve walked patients through this moment — when relief turns into uncertainty, and confidence feels shaken. That’s where Barricaid® comes in for the right patient: a small implant designed to reinforce a specific type of disc defect after discectomy, aiming to reduce the risk of symptomatic re-herniation (Thomé et al., 2021; Thomé et al., 2018).
Barricaid® isn’t for every patient, and that’s precisely why it matters. It’s not a default. It’s a decision backed by clinical evidence and aligned with a MotionFirst mindset: protect movement, reduce unnecessary rework, and help you return to life with greater confidence.
What Is Barricaid®?
Think of your spinal disc like a jelly doughnut.
The outer layer (the annulus) is tough and fibrous.
The inside (the nucleus) is softer and acts like a cushion.
A herniated disc happens when there’s a tear in the outer wall, and that inner material pushes out, irritating a nearby nerve. During a microdiscectomy, we remove the piece pressing on the nerve. For many, that brings dramatic relief.
But here’s what most people don’t realize: the tear in the disc wall often remains. And for certain patients, especially those with a larger defect, that weak spot can leave the disc more vulnerable to another herniation (Thomé et al., 2018).
Barricaid® was designed specifically for that situation. It’s an annular closure device, a titanium anchor with a flexible polymer barrier, intended to occlude a large annular defect after lumbar discectomy (Thomé et al., 2018; Thomé et al., 2021).
To make it plain:
- It doesn’t fuse the spine.
- It doesn’t restrict movement the way fusion might.
- It’s meant to reinforce the defect, so disc material is less likely to re-herniate through that opening (Thomé et al., 2018).
“Barricaid® is designed for a very specific problem,” says Dr. Woods, neurosurgeon and spine surgeon. “When the annular defect is large, the risk of re-herniation is higher. In the right patient, this device can reinforce that weak spot and reduce the chance of going through the same injury twice.”
Who Benefits Most from Barricaid®?
Barricaid isn’t for everyone, and that selectivity matters.
In clinical trials, the patients who benefited were those undergoing primary lumbar discectomy who were found (intraoperatively) to have a large annular defect, often defined as ≥6 mm in width (Thomé et al., 2018; Thomé et al., 2021). That’s a meaningful subgroup because large defects are associated with a higher recurrence risk, and that’s the specific problem Barricaid® is trying to address.
Practically, we think about Barricaid® when the story looks like this:
- symptoms consistent with sciatica from a lumbar disc herniation
- a single-level problem that matches imaging and exam
- conservative care has been tried, and the nerve is still not settling
- and during surgery, the defect size meets criteria similar to those studied (Thomé et al., 2018; Thomé et al., 2021)
On the other hand, Barricaid® is generally not considered when the anatomy doesn’t match the studies. For example, when the defect is small, or when other spine issues make a different strategy more appropriate. This is exactly why judgment matters more than the device itself.
Does Barricaid® Work? What the Research and Our Experience Show
Our patients often ask,
“Is this proven, or is it just new?”
That’s a fair question and one we take seriously.
From a research standpoint, the answer is reassuring.
Large randomized trials and post-market studies show that in patients with large annular defects, Barricaid® significantly reduces recurrence and reoperation rates without compromising clinical improvement.
Five-year outcomes tell the clearest story:
- Symptomatic re-herniation
- ~19% with Barricaid®
- ~32% with discectomy alone
- Reoperation rates
- ~50% relative risk reduction with Barricaid®
(Thomé et al., 2021)
Importantly, pain relief and functional improvement (VAS, ODI, SF-36) were equivalent between groups. Barricaid® doesn’t affect the effectiveness of surgery. It reduces how often it has to be repeated.
What We’ve Seen at Vertrae®
At Vertrae®, Barricaid® is used selectively for patients who meet criteria consistent with published clinical trials, particularly those with large annular defects and higher recurrence risk.
In our experience:
- Athletes and physically demanding professionals value the added protection Barricaid may provide
- Patients with significant annular defects often gain long-term confidence in recovery
- Preserving motion while reducing recurrence risk aligns directly with our MotionFirst philosophy
We’ve seen Barricaid® help the right patients return to high-level activity with less fear of “going through this again.”
That combination, strong long-term data plus real-world clinical experience, is what makes Barricaid meaningful. Not just as a new device, but as a carefully selected solution that protects outcomes well beyond the initial recovery.
What About Safety?
This question matters, especially with implants.
Across U.S. and European studies:
- Device- or procedure-related serious adverse events were lower with Barricaid® at 1 year (van den Brink et al., 2019)
- Overall serious adverse event rates were similar to discectomy alone at 3 years (Kienzler et al., 2019)
- Endplate changes were more common but largely asymptomatic and not linked to worse outcomes (Thomé et al., 2018)
Meta-analyses confirm:
~50% lower risk of both symptomatic re-herniation and reoperation
(Miller et al., 2020; Li et al., 2023)
What Happens During Surgery with Barricaid®?
From the patient’s perspective, the experience feels very similar to a standard microdiscectomy.
After the herniated disc fragment is removed, the surgeon evaluates the size of the annular tear. If Barricaid is appropriate, the device is anchored in place, and a small shield covers the opening in the disc wall.
The entire addition typically takes just a few extra minutes, but it can offer years of added protection.
Most patients go home the same day.
What Is Recovery Like After Barricaid®?
Recovery usually mirrors standard microdiscectomy recovery.
In the early weeks, walking is encouraged, and leg pain often improves quickly. Physical therapy typically follows, focusing on core stability, mobility, and confidence with movement.
After a few months out, many patients report not just relief, but reassurance. Knowing the disc has added protection allows people to move, lift, and live with less fear of another setback.
Why Doesn’t Every Spine Surgeon Offer Barricaid®?
Not every surgeon uses Barricaid®, and not every patient is a candidate. This device is designed for a specific situation, typically after microdiscectomy, when the annular defect is large enough to increase the risk of re-herniation.
It also requires careful intraoperative assessment, precise technique, and the right patient selection.
At Vertrae®, Barricaid® is used selectively by Dr. Kamal Woods, double fellowship–trained neurosurgeon and spine surgeon specializing exclusively in minimally invasive spine surgery, as part of a motion-preserving strategy designed to reduce recurrence risk in carefully select patients.
Is Barricaid® Right for You?
The answer depends on your anatomy, your symptoms, and, just as importantly, your goals.
At Vertrae®, a spine decision never starts with a device. It begins with understanding you.
Our spine specialists review your MRI, evaluate your movement, and discuss your lifestyle.
Sometimes Barricaid® is the right solution.
Sometimes, a microdiscectomy alone is enough.
Sometimes surgery isn’t needed at all.
What matters most is choosing the option that protects your long-term function, not just short-term relief.
That’s the foundation of our approach:
Preserve motion now, so you can keep moving for years to come.
Barricaid® is one tool within a thoughtful, motion-preserving system of spine care, and when used for the right patient, it can support a safer return to activity with greater confidence.
A Final Thought: Confidence Comes From Knowing Your Options
A herniated disc can shake your confidence.
A recurrence can make you hesitant to trust your body again.
For the right patient, Barricaid® offers more than pain relief. It provides reassurance.
Not because it’s “new” or “advanced,” but because it’s chosen carefully, explained clearly, and aligned with how you want to live.
If you’re wondering whether Barricaid® is right for you, or you want honest, experienced guidance about your options, we’re here.
Vertrae® proudly serves Dayton, the Greater Dayton area, and Southwest Ohio.
Let’s protect your motion and help you get back to living fully!
References
Kienzler, J. C., Klassen, P. D., Miller, L. E., et al. (2019). Three-year results from a randomized trial of lumbar discectomy with annulus fibrosus occlusion in patients at high risk for reherniation. Acta Neurochirurgica, 161(7), 1389–1396. https://doi.org/10.1007/s00701-019-03948-8
Li, W. S., Li, G. Y., Yan, Q., Chen, W. T., & Cong, L. (2023). Effectiveness and safety of annulus closure device implantation in lumbar discectomy: A systematic review and meta-analysis. European Spine Journal, 32(7), 2377–2386. https://doi.org/10.1007/s00586-023-07629-0
Miller, L. E., Allen, R. T., Duhon, B., & Radcliff, K. E. (2020). Expert review with meta-analysis of annular closure in patients at high risk for lumbar disc reherniation. Expert Review of Medical Devices, 17(5), 461–469. https://doi.org/10.1080/17434440.2020.1745061
Thomé, C., Klassen, P. D., Bouma, G. J., et al. (2018). Annular closure in lumbar microdiscectomy for prevention of reherniation. The Spine Journal, 18(12), 2278–2287. https://doi.org/10.1016/j.spinee.2018.05.003
Thomé, C., Kuršumovic, A., Klassen, P. D., et al. (2021). Effectiveness of an annular closure device to prevent recurrent lumbar disc herniation: A secondary analysis with 5 years of follow-up. JAMA Network Open, 4(12), e2136809. https://doi.org/10.1001/jamanetworkopen.2021.36809
van den Brink, W., Flüh, C., Miller, L. E., Klassen, P. D., & Bostelmann, R. (2019). Lumbar disc reherniation prevention with a bone-anchored annular closure device: 1-year results of a randomized trial. Medicine, 98(44), e17760. https://doi.org/10.1097/MD.0000000000017760
